These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32457995)

  • 21. Cefepime population pharmacokinetics and dosing regimen optimization in critically ill children with different renal function.
    de Cacqueray N; Hirt D; Zheng Y; Bille E; Leger PL; Rambaud J; Toubiana J; Chosidow A; Vimont S; Callot D; Chouchana L; Béranger A; Tréluyer JM; Benaboud S; Oualha M
    Clin Microbiol Infect; 2022 Oct; 28(10):1389.e1-1389.e7. PubMed ID: 35605841
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Monte Carlo Simulation Approach for Beta-Lactam Dosing in Critically Ill Patients Receiving Prolonged Intermittent Renal Replacement Therapy.
    Jang SM; Gharibian KN; Lewis SJ; Fissell WH; Tolwani AJ; Mueller BA
    J Clin Pharmacol; 2018 Oct; 58(10):1254-1265. PubMed ID: 29746711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Continuous-infusion antipseudomonal Beta-lactam therapy in patients with cystic fibrosis.
    Prescott WA; Gentile AE; Nagel JL; Pettit RS
    P T; 2011 Nov; 36(11):723-63. PubMed ID: 22346306
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dose optimization of piperacillin/tazobactam in critically ill children.
    De Cock PAJG; van Dijkman SC; de Jaeger A; Willems J; Carlier M; Verstraete AG; Delanghe JR; Robays H; Vande Walle J; Della Pasqua OE; De Paepe P
    J Antimicrob Chemother; 2017 Jul; 72(7):2002-2011. PubMed ID: 28387840
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Population pharmacokinetics of piperacillin/tazobactam in critically ill young children.
    Cies JJ; Shankar V; Schlichting C; Kuti JL
    Pediatr Infect Dis J; 2014 Feb; 33(2):168-73. PubMed ID: 23907263
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
    Marsot A; Hraiech S; Cassir N; Daviet F; Parzy G; Blin O; Papazian L; Guilhaumou R
    Int J Antimicrob Agents; 2020 Oct; 56(4):106124. PubMed ID: 32739478
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Monte Carlo Simulation Methodologies for β-Lactam/β-Lactamase Inhibitor Combinations: Effect on Probability of Target Attainment Assessments.
    Kidd JM; Stein GE; Nicolau DP; Kuti JL
    J Clin Pharmacol; 2020 Feb; 60(2):172-180. PubMed ID: 31423601
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modelled Target Attainment after Temocillin Treatment in Severe Pneumonia: Systemic and Epithelial Lining Fluid Pharmacokinetics of Continuous versus Intermittent Infusions.
    Layios N; Visée C; Mistretta V; Denooz R; Maes N; Descy J; Frippiat F; Marchand S; Grégoire N
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205221. PubMed ID: 35099273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Determinants of Target Non-Attainment of Linezolid in Plasma and Interstitial Space Fluid: A Pooled Population Pharmacokinetic Analysis with Focus on Critically Ill Patients.
    Minichmayr IK; Schaeftlein A; Kuti JL; Zeitlinger M; Kloft C
    Clin Pharmacokinet; 2017 Jun; 56(6):617-633. PubMed ID: 27753002
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous infusion of ceftazidime with a portable pump is as effective as thrice-a-day bolus in cystic fibrosis children.
    Rappaz I; Decosterd LA; Bille J; Pilet M; Bélaz N; Roulet M
    Eur J Pediatr; 2000 Dec; 159(12):919-25. PubMed ID: 11131352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma and target-site subcutaneous tissue population pharmacokinetics and dosing simulations of cefazolin in post-trauma critically ill patients.
    Roberts JA; Udy AA; Jarrett P; Wallis SC; Hope WW; Sharma R; Kirkpatrick CM; Kruger PS; Roberts MS; Lipman J
    J Antimicrob Chemother; 2015 May; 70(5):1495-502. PubMed ID: 25608584
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population pharmacokinetics of continuous infusion of piperacillin in critically ill patients.
    Dhaese SAM; Roberts JA; Carlier M; Verstraete AG; Stove V; De Waele JJ
    Int J Antimicrob Agents; 2018 Apr; 51(4):594-600. PubMed ID: 29277531
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Population Pharmacokinetics and Probability of Target Attainment of Different Dosing Regimens of Ceftazidime in Critically Ill Patients with a Proven or Suspected
    Werumeus Buning A; Hodiamont CJ; Lechner NM; Schokkin M; Elbers PWG; Juffermans NP; Mathôt RAA; de Jong MD; van Hest RM
    Antibiotics (Basel); 2021 May; 10(6):. PubMed ID: 34063815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.
    Sime FB; Hahn U; Warner MS; Tiong IS; Roberts MS; Lipman J; Peake SL; Roberts JA
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807922
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population Pharmacokinetic Study of the Suitability of Standard Dosing Regimens of Amikacin in Critically Ill Patients with Open-Abdomen and Negative-Pressure Wound Therapy.
    Carrié C; Delzor F; Roure S; Dubuisson V; Petit L; Molimard M; Breilh D; Biais M
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31964795
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics.
    Ulldemolins M; Roberts JA; Wallis SC; Rello J; Lipman J
    J Antimicrob Chemother; 2010 Aug; 65(8):1771-8. PubMed ID: 20530507
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determination of optimal loading and maintenance doses for continuous infusion of vancomycin in critically ill patients: Population pharmacokinetic modelling and simulations for improved dosing schemes.
    Vu DH; Nguyen DA; Delattre IK; Ho TT; Do HG; Pham HN; Dao XC; Tran NT; Nguyen GB; Van Bambeke F; Tulkens PM; Nguyen HA
    Int J Antimicrob Agents; 2019 Dec; 54(6):702-708. PubMed ID: 31600554
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ceftaroline pharmacokinetics and pharmacodynamics in patients with cystic fibrosis.
    Barsky EE; Pereira LM; Sullivan KJ; Wong A; McAdam AJ; Sawicki GS; Priebe GP; Goobie SM
    J Cyst Fibros; 2018 May; 17(3):e25-e31. PubMed ID: 29103924
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Population pharmacokinetic and pharmacodynamic modeling of high-dose intermittent ticarcillin-clavulanate administration in pediatric cystic fibrosis patients.
    Zobell JT; Stockmann C; Young DC; Cash J; McDowell BJ; Korgenski K; Sherwin CM; Spigarelli M; Chatfield BA; Ampofo K
    Clin Ther; 2011 Nov; 33(11):1844-50. PubMed ID: 22018680
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetics and Pharmacodynamics of Extended-Infusion Piperacillin and Tazobactam in Critically Ill Children.
    Nichols K; Chung EK; Knoderer CA; Buenger LE; Healy DP; Dees J; Crumby AS; Kays MB
    Antimicrob Agents Chemother; 2016 Jan; 60(1):522-31. PubMed ID: 26552978
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.